GlassScriptPhysician profile
Sameerah Rehmani
NPI 1245750538
$2,943.12
in general payments reported to CMS, 2019-2025
31 companies · $723 in 2025
The $723 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $88.42 · 2021: $332 · 2022: $559 · 2023: $823 · 2024: $417 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,963.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $588.11 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $450.32 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $347.55 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $258.49 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.00 | 2020-2025 | Jardiance |
| Lilly USA, LLC | $186.66 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $116.15 | 2021-2025 | Trelegy Ellipta, Bexsero, Penmenvy |
| Shield Therapeutics INC | $104.92 | 2024-2025 | |
| Amgen INC. | $101.16 | 2021-2025 | Repatha, Repatha, Otezla |
| Phadia US INC. | $59.15 | 2024-2025 | Immunocap |
| Sanofi-Aventis U.S. LLC | $58.87 | 2021-2025 | |
| Corium, LLC | $52.24 | 2022-2023 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $38.89 | 2022 | |
| Novartis Pharmaceuticals Corporation | $37.03 | 2023 | |
| Dexcom, INC. | $34.54 | 2024-2025 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $31.18 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $30.71 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $30.40 | 2021-2023 | Gardasil 9, Vaxneuvance |
| Allergan, INC. | $25.70 | 2020-2021 | |
| Abbott Laboratories | $25.51 | 2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $23.09 | 2021 | |
| Corcept Therapeutics | $20.71 | 2025 | Korlym |
| Sanofi Pasteur INC. | $18.20 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $17.61 | 2021 | |
| Esperion Therapeutics, INC. | $16.37 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.03 | 2024 | Nuzyra |
| Insulet Corporation | $15.11 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.87 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.68 | 2023 | Xarelto |
| Ironwood Pharmaceuticals, INC | $12.28 | 2021 | |
| Cranial Technologies, INC | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameerah Rehmani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.